bioRxiv (Cold Spring Harbor Laboratory) · 2023 · 41 citations · 65 references
Life SciencesInfectious DiseasesMolecular BiologyMolecular EvolutionMolecular VirologyVirologyEmerging Viral DiseasesViral EvolutionViral GeneticsViral Immune EvasionViral InfectionsViral PathogenesisAntigenic Variation In VirusesCirculationEmergenceEvasion Of Antibody Mediated ImmunityNeutralizing Antibody EvasionSars-cov-2 InfectionVariant Emergence StudiesViral Evasion Mechanisms
The unceasing circulation of SARS-CoV-2 leads to the continuous emergence of novel viral sublineages. Here, we isolated and characterized XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 and JN.1 variants, representing >80% of circulating variants in January 2024. The XBB subvariants carry few but recurrent mutations in the spike, whereas BA.2.86.1 and JN.1 harbor >30 additional changes. These variants replicated in IGROV-1 but no longer in Vero E6 and were not markedly fusogenic. They potently infected nasal epithelial cells, with EG.5.1.3 exhibiting the highest fitness. Antivirals remained active. Neutralizing antibody (NAb) responses from vaccinees and BA.1/BA.2-infected individuals were markedly lower compared to BA.1, without major differences between variants. An XBB breakthrough infection enhanced NAb responses against both XBB and BA.2.86 variants. JN.1 displayed lower affinity to ACE2 and higher immune evasion properties compared to BA.2.86.1. Thus, while distinct, the evolutionary trajectory of these variants combines increased fitness and antibody evasion.
65
Nextstrain: real-time tracking of pathogen evolution
James Hadfield, Colin Megill, Sidney M. Bell et al. · Bioinformatics · 2018 · 3.4K citations · Full text
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Delphine Planas, David Veyer, Artem Baidaliuk et al. · Nature · 2021 · 2.2K citations · Full text
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Raquel Viana, Sikhulile Moyo, Daniel G. Amoako et al. · Nature · 2022 · 1.9K citations · Full text
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Christopher O. Barnes, Claudia A. Jette, Morgan E. Abernathy et al. · Nature · 2020 · 1.9K citations · Full text